Consistent with these mechanistic insights, clinical analyses revealed that elevated levels of SAA1, IL1B, and CD33+ MDSCs were significantly correlated with poorer overall survival in EOC patients, underscoring the SAA1/IL-1β/MDSC axis as a key driver of tumor progression and adverse prognosis. Here, CD33 is linked to neoplasm.